Clostridium Difficile Colitis: Epidemiology, Diagnosis, Treatment, and Modalities
Abstract
Clostridium difficile infection (CDI) or Clostridium difficile colitis is an infection that causes significant morbidity and mortality. It accounts for 20-30% of antibiotic associated diarrhea and is occurring more often in the absence of antibiotics. It is the leading cause of hospital associated diarrhea. The organism has a remarkable ability to thrive outside of the colon, making hand washing and other preventative measures particularly important.
The diagnosis of CDI involves obtaining a stool specimen positive for toxigenic Clostridium difficile or Clostridium difficile toxins. Pseudomembranous colitis findings during colonoscopy may also be utilized to make the diagnosis. Polymerase chain reaction (PCR) test is the ideal testing method because it is highly sensitive and specific and results may be obtained in approximately one hour.
The treatment of CDI involves terminating the offending agent followed by antimicrobial therapy dictated by these classifications:
1) mild, moderate or severe
2) complicated vs. non-complicated
3) first episode, first recurrence or second recurrence
Metronidazole and vancomycin remain the initial treatment of choice, but other considerations such as possible offending agents, severity of disease and number of previous episodes are also of great importance. There are several other treatments available including fecal microbiota transplant although this is reserved for severe cases or third recurrences. However the best way to combat the disease remains through preventative measures such as proper hand sanitation.
References
Bobo LD. “Clostridium difficile in the ICU, The Struggle
Continues.” CHEST 2011; 140( 6 ): 1643 – 1653.
Borody TJ, Paramsothy S, Agrawal G. “Fecal microbiota transplantation: indications, methods, evidence, and future directions.” Curr Gastroenterol Rep. 2013 Aug;15(8):337.
Centers for Disease Control and Prevention. Morbidity and
Mortality Weekly Report. “Vital signs: Preventing Clostridium
difficile Infection.” MMWR Morb Mortal Wkly Rep. 2012;61
(09):157–62.
Chitnis, Amit et al. “Epidemiology of Community-Associated Clostridium difficile Infection, 2009-2011.” Jama Intern Med. 2013; 173(14):1359-1367.
Cohen, Stuart et al. Clinical Practice Guidelines for Clostridium difficile Infection In Adults: 2010 Update. Infect Control Hosp Epidemiol 2010; 31(5):431-455.
Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; “Fidaxomicin versus Vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.” Lancet Infect Dis. 2012 Apr;12(4):281-9.
Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL. “Fidaxomicin versus Vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.” Clin Infect Dis. 2012 Aug;55 Suppl 2:S93-103.
Dubberke E. “Strategies for Prevention of Clostridium difficile Infection.” Journal of Hospital Medicine. 2012;7:S14–S17.
El-Herte RI, Baban TA, Kanj SS. “Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.” Scand J Infect Dis. 2012 Mar;44(3):228-30.
Effective Health Care Program Comparative. Effectiveness Review Number 31. “Effectiveness of Early Diagnosis, Prevention, and Treatment of Clostridium difficile Infection.”
Foglia, G. ACAM-C. diffTM: An Active Vaccine against Clostridium difficile infection [abstract]. Presented at the 10th Anaerobic Society of the Americas. July 7-10 2010.
Hasty, Robert; Barbato, Vincenzo; Valdes, Pedro; Sitler, Christopher. “Clostridium difficile Treatment and Management.” Current Emergency and Hospital Medicine Reports.
Johnston BC et al. “Probiotics for the Prevention of Clostridium difficile–Associated Diarrhea A Systematic Review and Meta-analysis;” Ann Intern Med. 2012; 157:878-888.
Kassam Z, Lee CH, Yuan Y, Hunt RH. “Fecal microbiota
transplantation for Clostridium difficile infection: systematic
review and meta-analysis.” Am J Gastroenterol. 2013 Apr;108(4):500-8.
Kim, S.W. “Treatment of Refractory or recurrent Clostridium difficile Infection.” Korean J Gastroenterol.2012 Aug;60(2):71-8.
LaMont T. “Clostridium difficile in adults: Clinical manifestations and diagnosis.” http://uptodate.com. Literature review current through Mar 2014.
LaMont T. “Clostridium difficile in adults: Epidemiology,
microbiology, and pathophysiology.” http://uptodate.com. Literature review current through Mar 2014.
Larson KC, Belliveau PP, Spooner LM. “Tigecycline for the treatment of severe Clostridium difficile infection.” Ann Pharmacother. 2011 Jul; 45(7-8):1005-10.
Lao D, Chiang T, Gomez E. “Refractory Clostridium difficile
Infection Successfully Treated with tigecycline, rifaximin, and
vancomycin.” Case Rep Med. 2012; 2012:702910.
Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; “Fidaxomicin versus vancomycin for Clostridium difficile Infection.” N Engl J Med. 2011 Feb 3;364 (5):422-31.
Lowly, I Molrine DC et al. “Treatment with Monoclonal Antibodies against Clostridium difficile toxins.” N Engl J Med. 2010; 362:197-205
Surawicz, Christina et al. “Guidelines for the Diagnosis, Treatment, and Prevention of Clostridium difficile Infections.” Am J Gastroenterol 2013; 108:478–498.
Sheth S, LaMont T. “Toxic Megacolon.” http://uptodate.com. Literature review current through Jul 2013.
Tillotson, Glenn and Tillotson, Joni. “Clostridium difficile: A Moving Target.” F1000 Prime Reports. Published March 1, 2011. 3:6; doi:10.3410/M3-6.
Villano, SA et al. “Phase I Evaluation of an Oral Suspension VP20621 Spores of a Non-toxigenic Clostridium difficile Strain, M3, in Healthy Individuals.” Antimicrob Agents Chemother. 2012 Oct. 56(10):5224-5229.
American Academy of Pediatrics. Clostridium difficile. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LJ. (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.285.
Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ: European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15(12):1053.
Ferry G, Versalovic J. Antibiotic-associated colitis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.653.
Fekety R, Shah AB: Diagnosis and treatment of Clostridium difficile colitis. JAMA. 1993;269(1):71.
Important information about IND requirements for use of fecal microbiota to treat Clostridium difficile infection not responsive to standard therapies. US Food and Drug Administration. Available at: http://www.fda.gov.ezproxylocal.library.nova.edu/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm357258.htm (LAST ACCESSED 4/20/14)
Downloads
Published
How to Cite
Issue
Section
License
Accepted 2014-08-21
Published 2014-09-04
